Lakewood-Amedex Biotherapeutics, Inc.
- Market Cap (Standard market cap (price × shares outstanding) from the company profile — shown because the screener's float-computed cap is unavailable for this ticker.)
- $1.5M
- Price
- $0.8039
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.40%
- Volume
- 149.7K
About
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Quick stats
Shares outstanding—
Computed float1.6M
Float / sharesUnknown
Cash runway (months)7.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002079272
AI Summary
AI-generated1/22
minorbullishclinical trial
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Lakewood-Amedex announced positive preclinical data for its Bisphosphocin compounds in urinary tract and pulmonary infection animal models.
Intravesical Nu-8 achieved up to 97% inhibition of E. coli growth versus no effect in vehicle controls, and aerosolized Bisphosphocins showed in vivo activity against Acinetobacter, P. aeruginosa, and A. fumigatus.
The company plans to select a candidate for early clinical development, while lead asset Nu-3 (topical gel for infected diabetic foot ulcers) remains on track for Phase 2a topline data in Q1 2027.
Red flags
- Preclinical animal-model data may not translate to humans
- Early-stage biotech dependent on financing; forward-looking statements cite financing risks